Wolfgang Wick Selected Research

Ligands

11/2023	Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas.
8/2015	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.
4/2014	Microenvironmental clues for glioma immunotherapy.
5/2012	The aryl hydrocarbon receptor in tumor immunity.
10/2011	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
1/2007	Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
9/2006	Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
8/2002	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Wick Research Topics

Disease

240	Neoplasms (Cancer) 04/2024 - 08/2002
183	Glioblastoma (Glioblastoma Multiforme) 02/2024 - 08/2002
180	Glioma (Gliomas) 02/2024 - 03/2002
45	Brain Neoplasms (Brain Tumor) 02/2024 - 08/2005
29	Astrocytoma (Pilocytic Astrocytoma) 03/2024 - 10/2002
10	Meningioma (Meningiomas) 04/2024 - 11/2010
10	Stroke (Strokes) 11/2023 - 09/2012
10	Disease Progression 08/2023 - 09/2002
9	Oligodendroglioma 05/2023 - 10/2009
9	Melanoma (Melanoma, Malignant) 10/2019 - 08/2002
8	Thrombocytopenia (Thrombopenia) 01/2023 - 07/2012
7	Ischemic Stroke 11/2023 - 06/2017
7	Hypoxia (Hypoxemia) 11/2015 - 08/2002
6	Necrosis 01/2024 - 07/2006
6	Multiple Sclerosis 12/2023 - 05/2010
6	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2003
6	Medulloblastoma 05/2020 - 03/2002
5	Lymphopenia (Lymphocytopenia) 01/2022 - 12/2010
5	Neuroinflammatory Diseases 10/2019 - 09/2013
5	Infections 11/2016 - 07/2006
4	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2024 - 01/2019
4	Residual Neoplasm 01/2022 - 04/2017
4	Fatigue 01/2022 - 11/2016
4	Lymphoma (Lymphomas) 01/2022 - 12/2010
4	Seizures (Absence Seizure) 11/2021 - 08/2005

Drug/Important Bio-Agent (IBA)

76	Temozolomide (Temodar)FDA LinkGeneric 03/2024 - 03/2002
56	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 11/2023 - 10/2009
55	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2010
48	Bevacizumab (Avastin)FDA Link 12/2023 - 04/2010
38	Proteins (Proteins, Gene)FDA Link 12/2022 - 08/2002
25	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 02/2006
19	Lomustine (CCNU)FDA Link 10/2023 - 09/2006
19	MethyltransferasesIBA 01/2021 - 02/2006
17	EnzymesIBA 08/2023 - 05/2005
16	Tryptophan (L-Tryptophan)FDA Link 01/2021 - 01/2011
15	Alkylating AgentsIBA 03/2020 - 12/2005
14	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 08/2002
13	VaccinesIBA 01/2024 - 08/2014
13	Phosphotransferases (Kinase)IBA 01/2023 - 11/2004
12	Messenger RNA (mRNA)IBA 01/2022 - 06/2003
11	AntigensIBA 01/2024 - 02/2015
11	Transforming Growth Factors (Transforming Growth Factor)IBA 06/2017 - 10/2004
11	Transforming Growth Factor beta (TGF-beta)IBA 08/2009 - 10/2004
10	Vincristine (Oncovin)FDA LinkGeneric 05/2020 - 10/2002
9	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2018
9	Immune Checkpoint InhibitorsIBA 01/2023 - 08/2015
9	O(6)-Methylguanine-DNA MethyltransferaseIBA 07/2014 - 09/2008
8	LigandsIBA 11/2023 - 08/2002
8	Protons (Proton)IBA 10/2023 - 09/2010
8	O-(6)-methylguanineIBA 01/2021 - 02/2006
8	Procarbazine (Matulane)FDA Link 01/2020 - 10/2002
7	Peptides (Polypeptides)IBA 01/2024 - 08/2002
7	CarbonIBA 12/2023 - 09/2010
7	APTIBA 10/2023 - 06/2018
7	AmidesIBA 10/2023 - 05/2015
7	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2021 - 10/2011
7	KynurenineIBA 01/2021 - 01/2011
7	CilengitideIBA 03/2016 - 12/2009
7	CytokinesIBA 11/2014 - 11/2004
6	Contrast MediaIBA 12/2021 - 03/2012
6	ErbB Receptors (EGF Receptor)IBA 01/2021 - 10/2002
6	Essential Amino AcidsIBA 01/2020 - 09/2012
6	AntibodiesIBA 03/2019 - 04/2012
6	CaspasesIBA 02/2011 - 03/2002
5	Anticonvulsants (Antiepileptic Drugs)IBA 01/2024 - 08/2005
5	GadoliniumIBA 01/2024 - 01/2017
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2024 - 01/2021
5	Neoplasm Antigens (Tumor Antigens)IBA 01/2024 - 11/2018
5	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2023 - 04/2010
5	Protein Subunit VaccinesIBA 10/2023 - 01/2021
5	Histones (Histone)IBA 10/2023 - 05/2006
5	IonsIBA 01/2022 - 10/2010
5	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 12/2013
5	IntegrinsIBA 03/2016 - 12/2009
5	enzastaurinIBA 03/2016 - 09/2008
4	Angiogenesis InhibitorsIBA 11/2023 - 04/2010
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2023 - 01/2020
4	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023 - 01/2006
4	ParaffinIBA 12/2022 - 01/2012
4	alpha-hydroxyglutarateIBA 01/2022 - 01/2017
4	SteroidsIBA 01/2022 - 12/2010
4	Codon (Codons)IBA 01/2021 - 12/2010
4	Matrix Metalloproteinases (MMPs)IBA 01/2018 - 12/2004
4	Small Interfering RNA (siRNA)IBA 01/2015 - 10/2004
3	Coloring Agents (Dyes)IBA 02/2024 - 01/2018
3	CalciumIBA 02/2024 - 01/2019
3	NucleotidesIBA 01/2024 - 01/2016
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2024 - 01/2019
3	Lysine (L-Lysine)FDA Link 10/2023 - 01/2017

Therapy/Procedure

115	Therapeutics 02/2024 - 08/2002
85	Radiotherapy 04/2024 - 09/2002
66	Drug Therapy (Chemotherapy) 05/2023 - 09/2002
29	Immunotherapy 01/2023 - 01/2006
28	Chemoradiotherapy 05/2023 - 06/2008
8	Thrombectomy 11/2023 - 01/2018
4	Lasers (Laser) 12/2023 - 10/2017
4	Precision Medicine 01/2021 - 01/2010
4	Salvage Therapy 01/2020 - 09/2012
4	Re-Irradiation 12/2019 - 10/2010
4	Heavy Ion Radiotherapy 01/2018 - 09/2010